EVALUATION OF SERUM OSTEOCALCIN IN
ELDERLY PATIENTS WITH TYPE-2 DIABETES
MELLITUS.
DANIELA GRĂDINARU¹*, NICULINA MITREA¹, DENISA MARGINĂ¹,
ANDREEA ARSENE¹, VLAD GRUIA¹, CRISTINA DRĂGOI¹, ALINA
NICOLAE¹, CLAUDIA BORŞA², PETRE GHERASIM²
1Department of Biochemistry, Faculty of Pharmacy, University of
Medicine and Pharmacy “Carol Davila”, Bucharest6th Traian Vuia str,
Bucharest 2, 020956
2Ana Aslan National Institute of Gerontology and Geriatrics, Bucharest
*corresponding author: biochimiebucuresti@yahoo.com
Download Full Article

Abstract:

Osteocalcin, the second most abundant protein in bone tissue after collagen, is secreted by osteoblasts and thought to participate in mineralization and calcium ion homeostasis.
In addition to its use as biomarker in ostoporosis, experimental studies on mice published in Cell journal revealed for osteocalcin new metabolic functions, as hormone, being involved in blood glucose regulation, in insulin secretion, and in adipose tissue shaping. The aim of this study, conducted on 85 elderly patients (21 males and 64 females, aged 63-78 years) was to examine the relationship between serum osteocalcin concentration and classical biomarkers of investigation for glucose and lipid metabolism, using data from a clinical evaluation in elderly patients with impaired glucose tolerance and type-2 diabetes mellitus.

Top